Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-11-24
DOI
10.3389/fimmu.2022.880959
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Identification and prognostic value of a glycolysis-related gene signature in patients with bladder cancer
- (2021) Zhengyuan Wu et al. MEDICINE
- Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity
- (2021) Ke Xu et al. SCIENCE
- Proteogenomic and metabolomic characterization of human glioblastoma
- (2021) Liang-Bo Wang et al. CANCER CELL
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
- (2021) Ahmet Sezer et al. LANCET
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
- (2021) Roberta Zappasodi et al. NATURE
- Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
- (2021) McLane J. Watson et al. NATURE
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- Identification of novel cell glycolysis related gene signature predicting survival in patients with breast cancer
- (2021) Feng Jiang et al. Scientific Reports
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proteogenomic characterization of pancreatic ductal adenocarcinoma
- (2021) Liwei Cao et al. CELL
- A proteogenomic portrait of lung squamous cell carcinoma
- (2021) Shankha Satpathy et al. CELL
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
- (2021) Dean F. Bajorin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions
- (2021) Young-Sil An et al. Frontiers in Oncology
- Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
- (2021) Lukas Kraehenbuehl et al. Nature Reviews Clinical Oncology
- Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration
- (2020) Mounia Beloueche-Babari et al. BRITISH JOURNAL OF CANCER
- Proteogenomic Characterization of Endometrial Carcinoma
- (2020) Yongchao Dou et al. CELL
- Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity
- (2020) Fresia Pareja et al. MODERN PATHOLOGY
- Nine glycolysis-related gene signature predicting the survival of patients with endometrial adenocarcinoma
- (2020) JinHui Liu et al. Cancer Cell International
- Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Lisa Zimmer et al. LANCET
- Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
- (2020) Michael A. Gillette et al. CELL
- Integrative Proteomic Characterization of Human Lung Adenocarcinoma
- (2020) Jun-Yu Xu et al. CELL
- Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma
- (2020) Jiao Feng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Characterization of Glycolysis-Associated Molecules in the Tumor Microenvironment Revealed by Pan-Cancer Tissues and Lung Cancer Single Cell Data
- (2020) Jinfen Wei et al. Cancers
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
- (2020) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response
- (2020) A. Ari Hakimi et al. Nature Communications
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Seven-Gene Signature Based on Glycolysis Is Closely Related to the Prognosis and Tumor Immune Infiltration of Patients With Gastric Cancer
- (2020) Shanshan Yu et al. Frontiers in Oncology
- A glycolysis-related gene expression signature in predicting recurrence of breast cancer
- (2020) Jianing Tang et al. Aging-US
- The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma
- (2020) Fangshi Xu et al. BMC CANCER
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
- (2019) Suhas Vasaikar et al. CELL
- Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology
- (2019) Gregor Sturm et al. BIOINFORMATICS
- Emerging roles of aerobic glycolysis in breast cancer
- (2019) Z. Wu et al. Clinical & Translational Oncology
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic regulation of gene expression by histone lactylation
- (2019) Di Zhang et al. NATURE
- Correlation between 18F-FDG uptake on PET/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer
- (2019) Wakana Murakami et al. EUROPEAN JOURNAL OF RADIOLOGY
- Immunohistochemical Assessment of HRAS Q61R Mutations in Breast Adenomyoepitheliomas
- (2019) Fresia Pareja et al. HISTOPATHOLOGY
- Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma
- (2019) Lei Zhang et al. Journal of Translational Medicine
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- (2018) Katherine A. Hoadley et al. CELL
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2018) Hossein Borghaei et al. Journal of Thoracic Oncology
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response
- (2018) Inna Serganova et al. PLoS One
- The hallmarks of successful anticancer immunotherapy
- (2018) Lorenzo Galluzzi et al. Science Translational Medicine
- Strategies for Predicting Response to Checkpoint Inhibitors
- (2018) Roberta Zappasodi et al. Current Hematologic Malignancy Reports
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unique MicroRNA and mRNA Interactions in EGFR-Mutated Lung Adenocarcinoma
- (2018) Sophia Subat et al. Journal of Clinical Medicine
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
- (2016) Hui Zhang et al. CELL
- LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
- (2016) Almut Brand et al. Cell Metabolism
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism
- (2016) M. Peng et al. SCIENCE
- Intermediates of Metabolism: From Bystanders to Signalling Molecules
- (2016) Robert Haas et al. TRENDS IN BIOCHEMICAL SCIENCES
- Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
- (2015) Ping-Chih Ho et al. CELL
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy
- (2015) Helena Cirenajwis et al. Oncotarget
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene
- (2015) Arnaldur Hall et al. Oncotarget
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
- (2013) Chih-Hao Chang et al. CELL
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
- (2012) Patrick S. Ward et al. CANCER CELL
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers
- (2011) N. Palaskas et al. CANCER RESEARCH
- 18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis
- (2010) J. R. Osborne et al. JOURNAL OF NUCLEAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started